The Losartan Heart Failure ELITE Study recently found that in patients with symptomatic heart failure and a left ventricular ejection fraction of /=65 years with symptomatic heart failure. Data on health care resource utilization were collected as part of the trial. We conducted a cost-effectiveness analysis to estimate the lifetime benefits of treatment and the associated costs. We observed no differences between treatments in the number of hospitalizations, hospital days, and emergency room visits per patient over the trial period. We estimated the total cost of losartan to be USD 54 (95% CI: USD -1,717, USD 1,755) less per patient than captopril over this time frame. We also estimated that over the projected remaining lifetime of the study population, losartan compared to captopril would increase survival by 0.20 years (undiscounted) at an average cost of USD 769 (discounted) more per patient. This cost increase translated into a cost-effectiveness ratio of USD 4,047 per year of life gained for losartan relative to captopril. In patients with symptomatic heart failure, losartan compared to captopril increased survival with better tolerability at a cost well within the range accepted as cost-effective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000006908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of PGC-1α in the proliferation and metastasis of malignant tumors.
J Mol Histol
January 2025
Department of Thoracic Surgery, Lung Cancer Diagnosis and Treatment Center of Dalian, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.
Malignant tumors are among the major diseases threatening human survival in the world, and advancements in medical technology have led to a steady increase in their detection rates worldwide. Despite unique clinical presentations across the spectrum of malignancies, treatment modalities generally adhere to common strategies, encompassing primarily surgical intervention, radiation therapy, chemotherapy, and targeted treatments. Uncovering the genetic elements contributing to cancer cell proliferation, metastasis, and drug resistance remains a pivotal pursuit in the development of novel targeted therapeutics.
View Article and Find Full Text PDFEngineered heart muscle allografts for heart repair in primates and humans.
Nature
January 2025
German Centre for Cardiovascular Research (DZHK), Partner Site Lower Saxony, Göttingen, Germany.
Cardiomyocytes can be implanted to remuscularize the failing heart. Challenges include sufficient cardiomyocyte retention for a sustainable therapeutic impact without intolerable side effects, such as arrhythmia and tumour growth. We investigated the hypothesis that epicardial engineered heart muscle (EHM) allografts from induced pluripotent stem cell-derived cardiomyocytes and stromal cells structurally and functionally remuscularize the chronically failing heart without limiting side effects in rhesus macaques.
View Article and Find Full Text PDFPrediction of mortality in heart failure by machine learning. Comparison with statistical modeling.
Eur J Intern Med
January 2025
Istituti Clinici Scientifici Maugeri, IRCCS, Institute of Bari, Bari, Italy.
Background: Assessing the relative performance of machine learning (ML) methods and conventional statistical methods in predicting prognosis in heart failure (HF) still remains a challenging research field.
Methods: The primary outcome was three-year mortality. The following 5 machine learning approaches were used for modeling: Random Forest (RF), Gradient Boosting, Extreme Gradient Boosting (XGBoost), Support Vector Machine, and Multilayer perceptron.
Impact of pulmonary artery catheterization in patients with acute myocardial infarction cardiogenic shock.
Cardiovasc Revasc Med
January 2025
Department of Cardiology, MedStar Georgetown University Hospital/MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Acute myocardial infarction (AMI) remains one of the most common causes for cardiogenic shock (CS), with high inpatient mortality (40-50 %). Studies have reported the use of pulmonary artery catheters (PACs) in decompensated heart failure, but contemporary data on their use to guide management of AMI-CS and in different SCAI stages of CS are lacking. We investigated the association of PACs and clinical outcomes in AMI-CS.
View Article and Find Full Text PDFReliability of unicortical plate fixation for metacarpal shaft fractures: A preliminary clinical report with short-term follow-up.
Ann Chir Plast Esthet
January 2025
Department of Plastic and Reconstructive Surgery, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Republic of Korea.
Background: Unicortical plate fixation offers several theoretical advantages in the treatment of metacarpal shaft fractures compared to bicortical fixation. This approach avoids the potential hazard of excessive drilling into the volar cortex, thus minimizing damage to surrounding soft tissues and helping prevent complications related to improperly sized screws. These benefits prompted our team to conduct a preliminary clinical study to investigate the effectiveness and safety of this approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!